Autres langues Keymed Biosciences Inc.

Actions

2162

KYG5252B1023

Recherche biotechnologique et médicale

Marché Fermé - Hong Kong S.E. 10:08:52 07/10/2026			Varia. 5j.	Varia. 1 janv.
77,50 ^HKD	-2,58%		-4,97%	+45,00%

06/09	Keymed Biosciences Inc. annonce la démission de Min Chuan Wang de son poste de membre non exécutif du conseil d'administration, à compter du 4 septembre 2026	CI
03/09	Keymed Biosciences signe un accord de licence pour le Kangyueda sur 18 marchés	MT

Autres langues

06/09	Keymed Biosciences Inc. Announces Resignation of Min Chuan Wang as Non-Executive Director, Effective September 4, 2026
03/09	Keymed Biosciences Signs Licensing Deal for Kangyueda in 18 Markets
02/09	Keymed Biosciences Inc. and Aeira Pte. Ltd. Enter into Licensing Agreement for Stapokibart Injection in 18 Countries and Regions Including Southeast Asia and Central Asia
20/08	Keymed Biosciences Announces 2026 H1 Results and Business Updates
19/08	Keymed Biosciences Inc. Reports Earnings Results for the Half Year Ended June 30, 2026
12/08	Belenos Biosciences Announces Positive Topline Results from a Phase 2 Clinical Trial of BEL512 in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
10/08	Keymed Biosciences' Nasal Polyp Drug Trial Meets All Phase 2 Endpoints
10/08	Keymed Biosciences Inc. Announces Phase II Clinical Trial Results for CM512 Injection in Patients with Chronic Rhinosinusitis with Nasal Polyposis
28/07	Keymed Biosciences Inc. Achieves Positive Topline Results In Clarity-Gastric01 Global Phase III Clinical Trial For CMG901
28/07	Hong Kong Stocks Edge Higher Ahead of Central Bank Meetings; Keymed Biosciences Falls
28/07	Keymed Biosciences' Gastric Cancer Drug Meets Phase 3 Goal; Shares Fall 5%
28/07	Hong Kong-listed Keymed Biosciences' gastric cancer drug meets late-stage trial goals
23/07	Hong Kong Stocks Rise on Thursday; Tsaker New Energy Soars
23/07	Keymed Biosciences' CM512 Gets Breakthrough Therapy Designation in China; Shares up 4%
23/07	Keymed Biosciences Inc Includes CM512 In The Breakthrough Therapy Designation List By The Center For Drug Evaluation Of The National Medical Products Administration
16/07	Keymed Biosciences Expects Return to Profit in H1
05/06	Keymed Biosciences Receives $257 Million Upfront Payment After Gilead-Ouro Deal Close
05/06	Lakefront Biotherapeutics, Gilead Complete Ouro Acquisition for $1.68 Billion Upfront
04/06	Gilead Sciences, Inc. completed the acquisition of Ouro Medicines, Inc. from Keymed Biosciences Inc. and others.
27/03	Keymed Biosciences' Loss Deepens in 2025
26/03	Keymed Biosciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2025
24/03	Keymed Biosciences Says Ouro Medicines to be Sold in $2.18 Billion Deal
24/03	Keymed Biosciences disposes equity interest in- Ouro Medicines
23/03	Gilead Sciences, Inc. entered into a definitive agreement to acquire Ouro Medicines, Inc. from Keymed Biosciences Inc. and others for $2.2 billion.
11/03	Lepu Biopharma Says AstraZeneca Begins Phase 3 Trial of CMG901 Cancer Therapy; Shares Jump 7%